

**63<sup>rd</sup> American Society of Hematology Annual Meeting and Exposition**  
**December 11-14, 2021**  
**Georgia World Congress Centre**  
**Atlanta, Georgia**  
**Abstracts**

---

**CCTG ALC.5 / SWOG S1612: A Randomized Phase II/III Trial of Novel Therapeutics versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial)**

**Time:** Saturday, December 11, 2021: 2:45 PM  
**Location:** B308-B309, Georgia World Congress Centre  
**Type:** Oral  
**Session:** 613 – Acute Myeloid Leukemia: Clinical and Epidemiological: COVID and Beyond  
**Presenter:** Megan Othus  
**Abstract:** *Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG (#220)*  
**Authors:** Xu Wang, Ian Thomas, Cono Ariti, Mike Dennis, Priyanka Mehta, Nigel H Russel, Mia Sydenham, Robert Hills, Alan K. Burnett, Sucha Nand, Sarit Assouline, Laura C. Michaelis, Harry P. Erba, Kathleen Kerr, Roland B. Walter and **Megan Othus**  
**Link:** <https://ash.confex.com/ash/2021/webprogram/Paper151597.html>

---

**CCTG CLC.2 / Alliance A041202: A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients  $\geq$  to 65 years of age) with Chronic Lymphocytic Leukemia (CLL)**

**Time:** Sunday, December 12, 2021, 6:00-8:00 PM  
**Location:** Hall B5, Georgia World Congress Centre  
**Type:** Poster  
**Session:** 642 – Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II  
**Presenter:** Inhye E. Ahn  
**Abstract:** *Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial (#2642)*  
**Authors:** **Inhye E. Ahn**, Amy S. Ruppert, Adrian Wiestner, James S. Blachly, John C. Byrd, Richard M. Stone, Sumithra J Mandrekar and Jennifer A. Woyach  
**Link:** <https://ash.confex.com/ash/2021/webprogram/Paper153822.html>

---

**CCTG CLC.3 / SWOG S1925: Randomized Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus DeLayed Therapy with VEnetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study**

**Time:** Sunday, December 12, 2021: 6:00 – 8:00 PM

**Location:** Hall B5, Georgia World Congress Centre

**Type:** Poster

**Session:** 642 – Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III

**Presenter:** Deborah M. Stephens

**Abstract:** *Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG S1925; NCT#04269902) (#2630)*

**Authors:** Deborah M. Stephens, Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Fisch, Alexey V. Danilov, David Ng, Anthony R. Mato, Danielle M. Brander, Megan Othus, Steven Coutre, Susan M. O'Brien and Harry P. Erba

**Link:** <https://ash.confex.com/ash/2021/webprogram/Paper144780.html>

---

**CCTG CLC.2 / Alliance A041202: A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients  $\geq$  to 65 years of age) with Chronic Lymphocytic Leukemia (CLL)**

**Time:** Monday, December 13, 2021, 11:00 AM

**Location:** Thomas Murphy Ballroom 3-4, Georgia World Congress Centre

**Type:** Oral

**Session:** 642 – Chronic Lymphocytic Leukemia: Clinical and Epidemiological

**Presenter:** Jennifer A. Woyach

**Abstract:** *Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy (#639)*

**Authors:** Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry Rogers, Sameer A. Parikh, Steven Coutre, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, James S. Blachly, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Jennifer R Brown, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J Mandrekar and John C. Byrd

**Link:** <https://ash.confex.com/ash/2021/webprogram/Paper153146.html>

---

**CCTG LY.12: A Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Compared to Dexamethasone, Cytarabine, and Cisplatin Plus/Minus Rituximab [(R) -GDP VS (R) -DHAP] as Salvage Chemotherapy for Patients with Relapsed or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior to Autologous Stem Cell Transplant and Followed by Maintenance Rituximab Versus Observation**

**Time:** Monday, December 13, 2021: 6:00 – 8:00 PM

**Location:** Hall B5, Georgia World Congress Centre

**Type:** Poster

**Session:** 905 – Outcomes Research – Lymphoid Malignancies: Poster III

**Presenter:** Abi Vijenthira

**Abstract:** *Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial (#4076)*

**Authors:** Abi Vijenthira, Xinzhi Li, Michael Crump, Annette E. Hay, Lois E. Shepherd, Ralph Meyer, Marina S. Djurfeldt, Bingshu E. Chen and Anca Prisca

**Link:** <https://ash.confex.com/ash/2021/webprogram/Paper153037.html>

---

**CCTG ALC.1 / SWOG S0106: A Phase III Study Of The Addition Of Mylotarg? During Induction Therapy Verses Standard Induction With Daunomycin & Cytosine Arabinoside Followed By Consolidation & Subsequent Randomization To Post-Consolidation Therapy With Mylotarg? Or No Additional Therapy For Patients Under The Age Of 61 With Previously Untreated De Novo Acute Myeloid Leukemia**

**Time:** Monday, December 13, 2021: 6:00 – 8:00 PM

**Location:** Hall B5, Georgia World Congress Centre

**Type:** Poster

**Session:** 617 – Acute Myeloid Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster III

**Presenter:** Jacob Higgins

**Abstract:** *Duplex Sequencing for Ultra-Low Frequency Measurable Residual Disease Detection in Adult Acute Myeloid Leukemia (#3475)*

**Authors:** Jacob Higgins, Megan Othus, Laura W. Dillon, Thomas H. Smith, Elizabeth Schmidt, Jeffrey Yaplee, Fang Yin Lo, Charles C. Valentine III, Jesse J. Salk, Brent L. Wood, Christopher S. Hourigan and Jerald P. Radich

**Link:** <https://ash.confex.com/ash/2021/webprogram/Paper151509.html>

---